WKYMVM-NH2 TFA

WKYMVM-NH2 TFA is a potent N-formyl peptide receptor (FPR1) and FPRL1/2 agonist, also activates several leukocyte effector functions such as chemotaxis, mobilization of complement receptor-3, and activation of the NADPH oxidase[1][2][3].

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

WKYMVM-NH2 TFA (10-1000 nM; 24 hours) induces Caco-2 cells proliferation[3]. Cell Proliferation Assay[3] Cell Line: Caco-2 cells (the intestinal epithelial cells) Concentration: 0 nM, 10 nM, 100 nM, 1000 nM Incubation Time: 24 hours Result: Induced cell proliferation.

WKYMVM-NH2 TFA (8 mg/kg; six times; for 5 days) ameliorates DSS-induced ulcerative colitis[3]. WKYMVM-NH2 TFA affects cytokine (IL-17, IFN-γ, IL-6, IL-1β and TNF-α) profiles in the DSS colitis model[3]. Animal Model: Six-week-old C57BL/6 mice, DSS model[3] Dosage: 8 mg/kg Administration: Subcutaneously injected, six subcutaneous administrations at 12-h intervals, for 5 days Result: Attenuated the DSS-induced increase in the bleeding score and the stool score.

[1]. Christophe T, et al. The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J Biol Chem. 2001 Jun 15;276(24):21585-93.

[2]. Christophe T, et al. Phagocyte activation by Trp-Lys-Tyr-Met-Val-Met, acting through FPRL1/LXA4R, is not affected by lipoxin A4. Scand J Immunol. 2002 Nov;56(5):470-6.

[3]. Sang Doo Kim, et al. The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitis. Exp Mol Med. 2013 Sep; 45(9): e40.